Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity

William A Freed-Pastor; Andrew J Aguirre

doi:10.1016/j.ccell.2022.08.018

Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity

Cancer Cell. 2022 Sep 12;40(9):908-910. doi: 10.1016/j.ccell.2022.08.018.

Authors

William A Freed-Pastor¹, Andrew J Aguirre²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: william_freed-pastor@dfci.harvard.edu.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: andrew_aguirre@dfci.harvard.edu.

PMID: 36099887
DOI: 10.1016/j.ccell.2022.08.018

Abstract

Covalent inhibitors of oncogenic KRAS^G12C have demonstrated impressive clinical responses; however, therapeutic resistance has been commonly observed. In this issue, Zhang and colleagues demonstrate that small molecule KRAS^G12C inhibitors can generate haptenated major histocompatibility complex (MHC) class I:peptide complexes, which represent attractive targets for immune-based therapies to combat pharmacologic resistance.

Publication types

Comment

MeSH terms

Haptens
Humans
Oncogenes*
Proto-Oncogene Proteins p21(ras)* / genetics

Substances

Haptens
KRAS protein, human
Proto-Oncogene Proteins p21(ras)